CTOR vs TT · $105.2M cap vs P/E 36, rev $21.32B
Citius Oncology, Inc. (CTOR) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on US.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
CTOR does not have a complete income-statement cache yet.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
CTOR currently screens at market cap $105.2M. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the CTOR and TT stock pages for the full models.
Not investment advice.